Tech Company Financing Transactions

GenEdit Funding Round

GenEdit secured a $24 million Series A venture capital round on 1/23/2024. Investors included ACVC Partners, DAYLI Partners and Dong-A ST.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
The funding will support continued development of the NanoGalaxy platform and a pipeline of preclinical therapeutic candidates.

Company Information

Company Status
Private & Independent
Mailing Address
681 Gateway Blvd. 3rd Foor
San Francisco, CA 94080
Email Address
Not Recorded
GenEdit is a next-generation genome editing company. We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients.
GenEdit LinkedIn Company Profile
Social Media
GenEdit Company Twitter Account
Company News
GenEdit News
GenEdit on Facebook
GenEdit on YouTube

Management Team

Email & Social
Chief Executive Officer
Kunwoo Lee
  Kunwoo Lee LinkedIn Profile  Kunwoo Lee Twitter Account  Kunwoo Lee News  Kunwoo Lee on Facebook
Chief Financial Officer
Aaron Mishel
  Aaron Mishel LinkedIn Profile  Aaron Mishel Twitter Account  Aaron Mishel News  Aaron Mishel on Facebook
Chief Scientific Officer
Romuald Corbau
  Romuald Corbau LinkedIn Profile  Romuald Corbau Twitter Account  Romuald Corbau News  Romuald Corbau on Facebook
Chief Technical Officer
Timothy Fong
  Timothy Fong LinkedIn Profile  Timothy Fong Twitter Account  Timothy Fong News  Timothy Fong on Facebook
Vice President
Yvonne Angell
  Yvonne Angell LinkedIn Profile  Yvonne Angell Twitter Account  Yvonne Angell News  Yvonne Angell on Facebook
Vice President
Derek Sloan
  Derek Sloan LinkedIn Profile  Derek Sloan Twitter Account  Derek Sloan News  Derek Sloan on Facebook
VP - Bus. Development
Jennifer Cygan
  Jennifer Cygan LinkedIn Profile  Jennifer Cygan Twitter Account  Jennifer Cygan News  Jennifer Cygan on Facebook
VP - Operations
Hyo Park
  Hyo Park LinkedIn Profile  Hyo Park Twitter Account  Hyo Park News  Hyo Park on Facebook



Browse more venture capital transactions:

Prev: 1/23/2024: Elephas Biosciences venture capital transaction
Next: 1/23/2024: Daytrip venture capital transaction


Share this article


Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary